[Federal Register Volume 61, Number 227 (Friday, November 22, 1996)]
[Notices]
[Pages 59454-59455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-29894]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Production of Infectious Respiratory Syncytial Virus From Cloned
Nucleotide Sequences
PL Collins (NIAID)
Serial No. 08/720,132 filed 27 Sep 96 (claiming priority date of 27 Sep
95)
Licensing Contact: Robert Benson, 301/496-7056 ext 267
This invention is a method of producing infectious RSV from cDNA
encoding the RSV relicative intermediate RNA and cDNA encoding the N,
P, L and M2(ORF1) proteins of RSV, which are used to transfect a cell.
Claimed are cells or cell lysates comprising these cDNA molecules,
recombinant RSV and methods of producing the recombinant RSV. The
invention is particularly useful for producing mutant RSV as attenuated
RSV vaccine candidates. Mutations in the RSV genome known to have an
attenuated phenotype can be placed together in the RSV genome using
known techniques and made into infections in the RSV genome using known
techniques and made into infectious RSV using the invention. Vaccine
candidates can be stably stored as cDNA molecules and modified as
needed, for example to accommodate genetic drift in circulating RSV.
The invention is described in P.N.A.S. 92, 11563-11567, 1995. This
patent application has been foreign filed. (portfolio: Infectious
Diseases-Vaccines, viral, non-AIDS; Infectious Diseases-Research
Materials)
Glycoprotein Hormone Superagonists
MW Szkudlinski, BD Weintraub, M Grossman (NIDDK)
OTT Reference No. E-015-96/0 filed 08 May 96
Licensing Contact: J. Peter Kim, 301/496-7056 ext 264
The glycoprotein hormones, which include thyroid-stimulating
hormone, follicle-stimulating hormone, luteinizing hormone, and
chorionic gonadotropin, are involved in the development and regulation
of the ovary, testes, and thyroid. These hormones are heterodimers,
each consisting of a non-covalently linked alpha and beta subunit.
While the amino acid sequence of the beta subunit is hormone-specific,
that of the alpha subunit is identical in all hormones within the same
species. Embodied in the current invention are human glycoprotein
hormones which contain specific amino acid substitutions within the
alpha as well as beta subunits. These substitutions result in
glycoprotein hormone analogs, or ``superagonists,'' which exhibit a
significant increase in in vitro and in vivo bioactivity over the wild-
type hormone. These superagonists, therefore, appear to represent
potential agents for use in the treatment of a variety of conditions,
including various forms of male and female infertility and thyroid
carcinoma. (portfolios: Internal Medicine-Therapeutics, contraceptives;
Internal Medicine-Other)
Inhibitory and Non-Inhibitory Antigen Binding Polypeptides Against
Human P450 Enzymes
HV Gelboin, FJ Gonzalez (NCI)
Serial No. 08/559, 808 filed 17 Nov 95
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223
This invention concerns monoclonal antibodies (MAbs) specific for
particular members of the cytochrome P450 family of enzymes. The
cytochrome P450s are the metabolic interface between xenobiotics and
their metabolism in human and other species as well as for the
metabolism of endobiotics. A large array of drugs, mutagens,
carcinogens, pesticides, environmental chemicals, fatty acids, bile
acids, and steroids are metabolized by individual forms of cytochrome
P450. The invention involves the construction, isolation, and
production of MAbs that specifically bind to human cytochrome P450 3A3,
3A4, 3A5, and 2E1 and that specifically inhibit the enzyme activity of
human cytochrome P450 3A3, 3A4, and 3A5, and 2E1 (inhibitory MAbs) and
MAbs that specifically bind to cytochrome P450 3A3, 3A4, 3A5, and 2E1,
without inhibiting enzyme activity (non-inhibitory MAbs). Novel
inhibitory MAbs to human P450 have been in development for some time.
These MAbs can be used to assess adverse reactions in patients to
compounds and to identify populations that would exhibit different
sensitivities to the therapeutic or toxic effects of compounds.
Cytochrome P450 3A4 and 3A3 are very important members of the P450
family of enzymes. The human P450 3A4 and 3A3 metabolize a large
variety of drugs, steroids, and carcinogens. Cytochromes P450 3A3 and
3A4 are considered the most important P450s for a wide range of high
molecular weight substrates which include many of the known clinically
useful drugs, such as tranquilizers, antidepressants,
immunosuppressants, and anticancer drugs. Cytochrome P450 2E1 is
important because it metabolizes low molecular weight compounds
susceptible to environmental hazards and carcinogens. The human P450
2E1 also metabolizes clinically useful drugs such as the anesthetic
chlorzoxazone and the analgesic acetaminophen as well as caffeine.
Issuance of a patent for this invention is currently pending.
(portfolio: Internal Medicine-Miscellaneous; Cancer-Research Reagents,
MAb based; Internal Medicine-Diagnostics; Cancer-Diagnostics, in vitro,
MAb based)
Prevention of Progression in Vascular Disease
GE Striker, LJ Striker, FP Sherman (NIDDK)
Serial No. 08/478,347 filed 07 Jun 95
Licensing Contact: Carol Lavrich, 301/496-7056 ext 287
This invention relates to efficacious methods and pharmaceutical
compositions in the treatment of chronic progressive vascular diseases
(CPVD) characterized by scarring and/or fibrosis to halt and reverse
the disease process by resolving scar and fibrotic lesions. These
methods consist of the administration to patients of an effective
amount of Elmiron. The oral route of administration is preferred, with
total
[[Page 59455]]
daily dosage of Elmiron ranging from about 50 to 1200 mg per day. This
method of treatment utilizes a commercially available pharmaceutical
agent which may be administered by conventional means, while remaining
non-toxic and efficacious in the treatment of CPVD. (portfolio:
Internal Medicine--Therapeutics, cardiology)
Circularly Permuted Ligands and Circularly Permuted Fusion Proteins
IH Pastan, RJ Kreitman (NCI)
Serial No. 08/255,224 filed 08 Apr 94
Licensing Contact: Larry Tiffany, 301/496-7056 ext 206
Circularly permuted proteins are ligands wherein the amino and
carboxy ends have been joined together and new amino and carboxy ends
are formed at a different location in the ligand. The modified ligands
are as fully active as the original. The circularly permuted ligands
are especially useful when employed as a component in a fusion protein
of interest. Fusion proteins are polypeptide chains of two or more
proteins fused together in a single polypeptide chain. A fusion protein
may act as a potent cell-killing agent or as a linker to bind and
enhance the interaction between cells or cellular components to which
the protein binds, depending on the nature of the proteins being fused.
Therefore, fusion proteins have functional utility as a specific
targeting moiety to either kill or direct an immune response to cancer
cells. While some targeting moieties have shown lower specificity and
affinity for their targets when incorporated into fusion proteins, the
use of circularly permuted ligands improves the binding affinity of
certain fusion proteins. This invention provides novel ligands and
ligand fusion proteins that have a binding specificity and affinity
comparable to or greater than native ligand fusion proteins.
(portfolio: Cancer--Therapeutics, immunoconjugates, toxins; Cancer--
Therapeutcs, immunoconjugates, MAb)
Dated: November 14, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-29894 Filed 11-21-96; 8:45 am]
BILLING CODE 4140-01-M